news_6

Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer

BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today...

news_6

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

news_6

Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan

Netarsudil Ophthalmic Solution 0.02% Once Daily Demonstrated Superiority to Ripasudil 0.4% Twice Daily DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an...

news_6

COVID-19: Cytokine Storm and Coagulopathy Markers Controlled With Nichi Glucan Variants; The First of Its Kind Report in a Clinical Study

IL-6, D-Dimer well managed for long, with clinically beneficial immune modulation. TOKYO--(BUSINESS WIRE)--Cytokine storm and coagulopathy, the major life-threatening complications...